Table 4.
Multivariate analysis of factors affecting on survival outcomes
| Progression-free survival | Overall survival | |||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Age | 0.95 (0.92–0.99) | 0.012 | – | – |
| LDH > normal | – | 3.01 (.38–6.58) | <0.001 | |
| β2 microglobulin ≥ 5.5 mg/L | 2.91 (1.68–5.02) | <0.001 | – | – |
| Pre-ASCT | – | – | ||
| CR | 1 | |||
| VGPR | 3.14 (1.20–8.21) | 0.05 | – | – |
| PR | 5.96 (1.93–18.39) | 0.009 | – | – |
| Post-ASCT at 3 months | ||||
| CR | 1 | 1 | ||
| VGPR | 1.24 (0.68–2.25) | 0.557 | 4.21 (1.71–10.37) | 0.009 |
| PR | 1.97 (0.86–4.54) | 0.179 | 2.15 (0.56–8.24) | 0.35 |
| PD | 53.2 (15.8–178.9) | <0.001 | 23.7 (7.13–78.75) | <0.001 |
HR hazard ratio, CI confidence interval, LDH lactate dehydrogenase, CR complete response, VGPR very good partial response, PR partial response, PD progressive disease